Mereo BioPharma Group PLC ADR is a biotechnology business based in the US. Mereo BioPharma Group PLC ADR shares (MREO) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.67 – an increase of 6.8% over the previous week. Mereo BioPharma Group PLC ADR employs 36 staff and has a trailing 12-month revenue of around $1 million.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $2.67 |
|---|---|
| 52-week range | $1.58 - $5.02 |
| 50-day moving average | $2.38 |
| 200-day moving average | $3.48 |
| Wall St. target price | $7.72 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.30 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.67 from 2025-05-02
| 1 week (2025-04-25) | 6.80% |
|---|---|
| 1 month (2025-04-04) | 34.17% |
| 3 months (2025-02-04) | -15.51% |
| 6 months (2024-11-04) | -33.42% |
| 1 year (2024-05-03) | -18.10% |
|---|---|
| 2 years (2023-05-03) | 115.32% |
| 3 years (2022-05-03) | 323.81% |
| 5 years (2020-05-04) | 111.90% |
| Revenue TTM | $1 million |
|---|---|
| Gross profit TTM | $936,000 |
| Return on assets TTM | -39.99% |
| Return on equity TTM | -77.58% |
| Profit margin | 0% |
| Book value | $0.39 |
| Market Capitalization | $424.5 million |
TTM: trailing 12 months
We're not expecting Mereo BioPharma Group PLC ADR to pay a dividend over the next 12 months.
Over the last 12 months, Mereo BioPharma Group PLC ADR's shares have ranged in value from as little as $1.575 up to $5.02. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Mereo BioPharma Group PLC ADR's is 0.654. This would suggest that Mereo BioPharma Group PLC ADR's shares are less volatile than average (for this exchange).
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab, an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for use in the treatment of tumors. The company is also developing Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod, a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole, an oral aromatase inhibitor, which is in Phase 2 trials for use in the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab, an antibody for the treatment of osteogenesis imperfecta; and Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; and licensing agreement with AstraZeneca. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, United Kingdom. .
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Some of the best stock trading apps for beginners include SoFi, Robinhood, Public, Stash, Opto and more. Compare your options here.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
Compare the 7 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
Fidelity is best for its extensive tools and resources, while Robinhood is a popular choice for its simple, easy-to-use platform.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .